Extended-Release Venlafaxine Research Overview
Venlor XR 75 mg Cipla is an extended-release pharmaceutical formulation containing venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI). This compound represents a significant advancement in dual neurotransmitter modulation research, offering researchers an opportunity to examine sustained-release pharmacokinetics in laboratory settings. The 75mg dosage strength provides a standardised concentration for analytical studies investigating neurotransmitter pathway interactions. Research teams at Stroid UK Shop utilise this pharmaceutical-grade formulation alongside other compounds in their venlafaxine research collection to advance understanding of dual-action reuptake inhibition mechanisms.
Laboratory Applications and Research Protocols
Laboratory studies examine venlafaxine’s mechanism through inhibition of serotonin and norepinephrine reuptake transporters, with additional weak inhibition of dopamine reuptake at higher concentrations. The extended-release matrix technology enables researchers to investigate sustained pharmacokinetic profiles versus immediate-release formulations. In-vitro receptor binding assays evaluate venlafaxine’s selectivity for monoamine transporters compared to other neurotransmitter systems. Analytical chemistry protocols focus on the compound’s metabolic pathways, particularly the formation of the active metabolite O-desmethylvenlafaxine. Research teams studying neurochemical modulation often compare venlafaxine mechanisms with compounds available in our SARMs collection and peptides research range to understand diverse receptor interaction profiles.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Venlafaxine Hydrochloride |
| Strength | 75mg per tablet |
| Formulation | Extended-release matrix tablet |
| Manufacturer | Cipla Limited |
| CAS Number | 99300-78-4 (venlafaxine HCl) |
| Molecular Formula | C₁₇H₂₇NO₂·HCl |
| Molecular Weight | 313.87 g/mol |
| Storage Requirements | Room temperature, dry environment |
Research Compliance and Safety
This venlafaxine research material is supplied exclusively for in-vitro laboratory analysis and educational research purposes. The extended-release formulation requires appropriate analytical methods to study drug release kinetics and dissolution profiles in controlled laboratory environments. Researchers must maintain proper storage conditions and handle the compound according to institutional safety protocols. Laboratory personnel should implement appropriate analytical procedures when investigating neurotransmitter modulation mechanisms or pharmaceutical formulation characteristics. This product is not intended for human consumption, therapeutic use, or any application outside controlled research environments. All research must comply with applicable laboratory safety guidelines and regulatory requirements for pharmaceutical research materials.
